Skip to main content

Table 4 Past studies on salvage RT for biochemical recurrence after RP

From: Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml

Study Patients (n) Median pre-RT PSA (ng/ml) prognostic factors after salvage RT bRDS(%)
Hagan et al [7] 91 4.5 pre-RT PSA (< 1.0 ng/ml) 55 (5-year)
Quero et al [8] 59 1.43 pre-RT PSA (< 1.0 ng/ml) 41.2 (5-year)
Macdonald et al [9] 121 1.4 pre-RT PSA (< 0.2 ng/ml) NA
Anscher et al [10] 89 1.4 pre-RT PSA (< 2.5 ng/ml), RT dose (> 65 Gy) 50 (4-year)
Chawla et al [20] 54 1.3 Gleason score (≤ 6), time to detectable postoperative PSA 35 (5-year)
Tsien et al [21] 57 1.2 Gleason score (< or = 7) 58 (5-year)
Neuhof et al [4] 171 1.1 Gleason score (< 7), pre-RT PSA (< 1.0 ng/ml) 35.1 (5-year)
Jacinto et al [22] 43 0.87 PSADT (> 4.0 months) 71 (3-year)
Taylor et al [23] 66 0.8 delayed rise in PSA after RP 66 (5-year)
Pazona et al [11] 307 0.8 pre-RT PSA (< 1.3 ng/ml), Seminal vesicle 40 (5-year)
Stephenson et al [6] 501 0.72 Gleason score (≤ 7), pre-RT PSA (≤ 2.0 ng/ml),
PSADT (> 10 months)
45 (4-year)
Buskirk et al [12] 368 0.7 pT2-3a, Gleason score (≤ 7), Pre-RT PSA (< 1.0 ng/ml) 46 (5-year)
Bernard et al [13] 364 0.6 RT dose (> 66.6 Gy, patients with pre-RT PSA < 0.6 ng/ml) 50 (5-year)
Ward et al [24] 211 0.6 PSADT (> 12 months) 34 (10-year)
King et al [25] 37 0.49 PSAV (≤ 1.0 ng/ml/year) NA
Wiegel et al [26] 162 0.33 PSA undetectable after salvage RT (< 0.1 ng/ml) 54 (3.5-year)
Tomita et al [27] 51 0.25 PSADT (> 3.0 months), Gleason Score, RT dose (≥ 60 Gy) 55.1 (3-year)
Terai et al [14] 37 0.146 cT1-2, pT2, pre-RT PSA (> 0.15 ng/ml) 54 (5-year)
  1. Abbreviations: RT = radiotherapy, RP = radical prostatectomy, PSA = prostate-specific antigen, bRDS = biochemical relapse-free survival, PSADT = PSA doubling time, PSAV = PSA velocity, NA = not available